A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety

  • Authors:
    • John L. Hays
    • Geoff Kim
    • Amanda Walker
    • Christina M. Annunziata
    • Jung-Min Lee
    • Jennifer Squires
    • Nicole Houston
    • Seth M. Steinberg
    • Elise C. Kohn
  • View Affiliations

  • Published online on: March 20, 2013     https://doi.org/10.3892/mco.2013.99
  • Pages: 565-569
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The anti-angiogenic activity of L‑asparaginase (L‑ASP) and the sensitivity of ovarian cancer cell lines to L‑ASP has been previously demonstrated by preclinical findings. The aim of this clinical trial was to translate those findings and evaluate the activity of polyethylene glycol‑conjugated L‑asparaginase (PEG-ASP or pegaspargase) in advanced ovarian cancer. Women with recurrent ovarian cancer and good end‑organ function were enrolled in an open‑label phase II trial of PEG-ASP at a dose of 2,000 IU/m2 by intravenous infusion every 2 weeks. Patients were evaluated for response every 8 weeks and for toxicity on an ongoing basis. Early stopping rules for toxicity and activity were included. Four patients were enrolled and received a total of 7 treatment cycles. The study ended accrual by invoking an early stopping rule, after excessive toxicity was identified in patients. Drug-related toxicities included grade 2 pancreatitis, fatigue, neutropenia, hypoalbuminemia, weight loss, dehydration, decreased fibrinogen and 1 case of grade 3 hypersensitivity reaction during cycle 2. One patient died during the study. No patients were evaluable for response. PEG-ASP was poorly tolerated in this group of advanced‑stage ovarian cancer patients and no conclusions regarding activity may be drawn. Further studies of PEG-ASP in ovarian cancer patients are not recommended.
View References

Related Articles

Journal Cover

May-June 2013
Volume 1 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hays JL, Kim G, Walker A, Annunziata CM, Lee J, Squires J, Houston N, Steinberg SM and Kohn EC: A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety. Mol Clin Oncol 1: 565-569, 2013
APA
Hays, J.L., Kim, G., Walker, A., Annunziata, C.M., Lee, J., Squires, J. ... Kohn, E.C. (2013). A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety. Molecular and Clinical Oncology, 1, 565-569. https://doi.org/10.3892/mco.2013.99
MLA
Hays, J. L., Kim, G., Walker, A., Annunziata, C. M., Lee, J., Squires, J., Houston, N., Steinberg, S. M., Kohn, E. C."A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety". Molecular and Clinical Oncology 1.3 (2013): 565-569.
Chicago
Hays, J. L., Kim, G., Walker, A., Annunziata, C. M., Lee, J., Squires, J., Houston, N., Steinberg, S. M., Kohn, E. C."A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety". Molecular and Clinical Oncology 1, no. 3 (2013): 565-569. https://doi.org/10.3892/mco.2013.99